The Immune Response Corporation to Present at EQUITIES Magazine Transatlantic Corporate Conference; Company to Present in New York, London and Milan, September 15-20

The Immune Response Corporation (OTCBB:IMNR), animmuno-pharmaceutical company developing products to treat autoimmuneand infectious diseases, announced it will be presenting at theEQUITIES Magazine Corporate Transatlantic Conference. President andCEO Dr. Joseph O'Neill will make presentations to sophisticatedaudiences of brokers, fund managers, investment professionals andactive retail investors about the progress the Company has made sinceannouncing its new corporate and clinical strategy last February. Dr.O'Neill's presentation will include updates on advances in theclinical programs of IRC's two lead immune-based therapies:NeuroVax(TM) for multiple sclerosis (MS) and IR103 for HIV/AIDS.

The EQUITIES Transatlantic Conference is scheduled for September15, at the American Stock Exchange, New York City; September 18, atthe AIM London Stock Exchange, London; and September 20, at the BorsaItaliana Stock Exchange, Milan.

The Immune Response Corporation's presentation will be webcastlive on September 15, 12:00 noon EDT, from the New York City event.

In order to listen to the presentation and view the slides, usethe following URL: http://www.visualwebcaster.com/equitiesmag/amex2006/event.html. Toensure you can access the presentation, please check the above URLearly for web browser compatibility.

The presentation will also be archived for 90 days on theCompany's website which you can access at:http://www.imnr.com/ir/ir_presentations.htm.

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is animmuno-pharmaceutical company focused on developing products to treatautoimmune and infectious diseases. The Company's lead immune-basedtherapeutic product candidates are NeuroVax(TM) for the treatment ofMS and IR103 for the treatment of HIV infection. Both of thesetherapies are in Phase II clinical development and are designed tostimulate pathogen-specific immune responses aimed at slowing orhalting the rate of disease progression.

NeuroVax(TM), which is based on the Company's patented T-cellreceptor (TCR) peptide technology, has shown potential clinical valuein the treatment of relapsing forms of MS. NeuroVax(TM) has been shownto stimulate strong, disease-specific cell-mediated immunity in nearlyall patients treated and appears to work by enhancing levels of FOXP3+Treg cells that are able to down regulate the activity of pathogenicT-cells that cause MS. Increasing scientific findings have associateddiminished levels of FOXP3+ Treg cell responses with the pathogenesisand progression of MS and other autoimmune diseases such as rheumatoidarthritis (RA), psoriasis and Crohn's disease. In addition to MS, theCompany has open Investigational New Drug Applications (IND) with theFDA for clinical evaluation of TCR peptide-based immune-basedtherapies for RA and psoriasis.

IR103 is based on the Company's patented, whole-inactivated virustechnology, co-invented by Dr. Jonas Salk and indicated to be safe andimmunogenic in extensive clinical studies of REMUNE(R), the Company'sfirst generation HIV product candidate. IR103 is a more potentformulation that combines its whole-inactivated antigen with asynthetic Toll-like receptor (TLR-9) agonist to create enhancedHIV-specific immune responses. The Company is currently testing IR103in two Phase II clinical studies as a first-line treatment fordrug-naive HIV-infected individuals not yet eligible forantiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The ImmuneResponse Corporation and are not approved by any regulatory agenciesin any country at this time. Please visit The Immune ResponseCorporation at www.imnr.com.

This news release contains forward-looking statements.Forward-looking statements are often signaled by forms of words suchas should, could, will, might, plan, projection, forecast, expect,guidance, potential and developing. Actual results could varymaterially from those expected due to a variety of risk factors,including whether the Company will continue as a going concern andsuccessfully raise proceeds from financing activities sufficient tofund operations and additional clinical trials of NeuroVax(TM) orIR103, the uncertainty of successful completion of any such clinicaltrials, the fact that the Company has not succeeded in commercializingany drug, the risk that NeuroVax(TM) or IR103 might not prove to beeffective as either a therapeutic or preventive vaccine, whetherfuture trials will be conducted and whether the results of such trialswill coincide with the results of NeuroVax(TM) or IR103 in preclinicaltrials and/or earlier clinical trials. A more extensive set of risksis set forth in The Immune Response Corporation's SEC filingsincluding, but not limited to, its Annual Report on Form 10-K for theyear ended December 31, 2005, and its subsequent Quarterly Reportsfiled on Form 10-Q. The Company undertakes no obligation to update theresults of these forward-looking statements to reflect events orcircumstances after today or to reflect the occurrence ofunanticipated events.

REMUNE(R) is a registered trademark of The Immune ResponseCorporation. NeuroVax(TM) is a trademark of The Immune ResponseCorporation.